It was revealed on Monday that Hologic HOLX is set to purchase Gen-Probe GPRO for approximately $3.72 billion. This is an all-cash deal that will see the Bedford, Mass.-based company pay $82.75 for each GPRO share. The move will see HOLX seek to broaden its diagnostics business.
"This transaction establishes Hologic as a premier company in [sexually transmitted disease] diagnostics and advances our core focus on women's health," said Rob Cascella, Hologic's CEO, adding that it will help the company "capitalize on the fast-growing molecular diagnostics market with an established global infrastructure."
Following the acquisition, HOLX's per-share earnings are expected to be boosted by 20 cents in the first fiscal year, and more afterwards.
So what will Gen-Probe bring to Hologic? Well, its diagnostic products include tests for STDs (including chlamydia and gonorrhea), human papillomavirus and trichomonas.
The newly-combined company is expected bring in annual revenue of roughly $2.4 billion, with adjusted earnings before interest, taxes, depreciation and amortization of $822 million.
With Hologic looking to broaden its diagnostic base, it really seems like an inspired move to purchase GPRO, which also markets a range of nucleic acid tests (NATs), to detect infectious micro-organisms, including those causing tuberculosis, strep throat, and other infections.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in